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Adjuvant intraoperative photodynamic therapy diminishes the rate oflocal
recurrence in a rat mammary tumour model
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Summary The use of photodynamic therapy (PDT) as an adjunct to curative tumour resection was inves-
tigated in a tumour recurrence model, using rat mammary adenocarcinoma BN472. Tumours were inoculated
subcutaneously in 60 animals and resected after 21 days of growth. Immediately after removal, the operation
site was exposed to 320-450 nm light of 0.1 W cm2 and 60 J cm-2 after photosensitisation with either
Photofrin (5 mg kg-' i.v. 48 h before illumination) or 5-aminolaevulinic acid (ALA) (2mgml-' in drinking
water for 9 days). Porphyrin concentrations were measured in tissue samples. After 28 days, animals treated
with adjunctive PDT had a significantly longer tumour-free interval than controls (P<0.01); median 25 days
(Photofrin), 18 days (ALA), 14 days (controls). Moreover, in the PDT groups significantly fewer rats had
lymph node metastasis. A porphyrin concentration ratio between tumour and mammary tissue of 2:1 was
found after Photofrin and 4:1 after ALA. The results indicate that adjuvant intraoperative PDT may be a safe
and effective method of destroying residual tumour, thereby preventing locoregional tumour recurrence.
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Despite radical surgery and perioperative chemo- or radio-
therapy, local regional recurrence remains one of the major
problems in cancer treatment. Most disappointing are the
results of resection of pancreatic adenocarcinoma, in which
local recurrence has been found in more than 80% at
autopsy (Kayahara et al., 1993); Westerdahl et al., 1993). In
colorectal cancers (Dukes' B2-C), isolated locoregional
disease accounts for 15-34% of the 50% ofpatients that can
be expected to experience recurrence (Moertel et al., 1990;
Galandiuk et al., 1992). For breast cancer, local recurrence
rates of 5-30% have been reported after radical mastectomy
and 2-21% after breast-conserving surgery combined with
post-operative radiotherapy (Fisher et al., 1989; Ames and
Balch, 1990; MacMillan et al., 1994). These recurrences are
thought to arise from microscopic residual tumour, owing to
incomplete removal or contamination by the surgical
manipulation (Holland et al., 1985; Buyse et al., 1988;
Frazier et al., 1989). Thus, there is clearly a need for an
adjuvant treatment that would sterilise the tumour bed intra-
operatively with minimal or no side-effects.
Photodynamic therapy (PDT) could be especially suitable
for that purpose. PDT is a relatively new local cancer treat-
ment that has been used successfully in patients with bron-
chus, bladder, skin and gastrointestinal tumours (Dougherty,
1993). The therapy is based on the accumulation of a
photosensitiser in malignant tissues after local or systemic
administration. Subsequent illumination with light of the
appropriate wavelength creates a photochemical reaction re-
sulting in tissue destruction (Gomer, 1989).
The most commonly used photosensitiser is porfimer
sodium, an aggregated mixture of trimer/oligomer porphyrin
molecules marketed as Photofrin (QLT, Vancouver, Canada,
and Cyanamid, Pearl River, NY, USA). This substance is an
effective photosensitiser, however accumulation in normal
organs and prolonged skin photosensitivity have limited its
application (Razum et al., 1987; Bellnier et al., 1989).
Recently, the use of 5-aminolaevulinic acid (ALA) as a
means of endogenous photosensitisation has received much
interest. We found that oral administration of ALA causes
selective accumulation of protoporphyrin IX (PROTO) in a
transplantable rat colon carcinoma (Van Hillegersberg et al.,
1992). With ALA, the photosensitivity is limited to a period
less than 24 h (Pottier et al., 1986; Loh et al., 1993). The
reason for selective porphyrin accumulation in malignant
tissue after ALA may be an altered activity of the haem
biosynthetic pathway enzymes. Several studies have reported
a higher activity of porphobilinogen deaminase (PBGD) in
malignant and regenerating cells, whereas the opposite was
found for ferrochelatase (Smith, 1987; Schoenfeld et al.,
1988). PBGD catalyses the formation of uroporphyrinogen
(URO) from four molecules of porphobilinogen and fer-
rochelatase converts protoporphyrin to haem.
The aim of the present study was to investigate the effect
ofadjuvant intraoperative PDT on tumour recurrence as well
as lymph node and lung metastases, following curative
tumour resection. An aggressively growing rat mammary
tumour was used for the experiments with either Photofrin or
ALA as photosensitisers. Additionally, porphyrin concentra-
tion, ferrochelatase and PBGD activity were measured in
tumour and surrounding tissue to study the accumulation of
photoactive agents.
Materials and methods
Animals and tumour model
Sixty female BN rats (Harlan CPB, Zeist, The Netherlands),
weighing 200-225 g, were used for the experiments. They
had free access to tap water (acidified, pH 3.0) and rat chow
(AM II, Hope Farms, Woerden, The Netherlands).
Mammary tumour BN472 was chosen for this particular
study, as it grows invasively from the inoculation site, meta-
stasises to regional lymph nodes and lungs, and mostly recurs
at the operation site despite complete macroscopic excision
(Kort et al., 1986a). The tumour is a moderately differen-
tiated adenocarcinoma, originating from a BN female rat in
one of our studies on spontaneous tumour incidence (Kort et
al., 1986b).
From tumour maintained in syngeneic animals, pieces of
approximately 1 mm3 were inoculated subcutaneously in the
right flank (abdominal lateral) of each animal. Twenty-one
days later, the tumours had macroscopically not invaded the
surrounding tissues and were dissected carefully from the
abdominal wall and overlying skin. Tumour diameter was
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measured using sliding callipers. Hypnorm (Janssen Phar-
maceutica, Tilburg, The Netherlands) 0.1 ml i.m. was given
to relieve post-operative pain. All procedures were performed
under ether anaesthesia.
Photosensitisation
The animals were randomly allocated to three groups of 20
each. In two experimental groups the animals received either
Photofrin in a single intravenous dose of 5 mg kg-' body
weight on day 19 post tumour inoculation or a solution of
ALA-HCI (Sigma, St Louis, MO, USA), 2 mg ml-' in drink-
ing water, from days 12 to 21. As the water intake of rats of
this species and weight is approximately 10 ml day-', the
daily ALA dosage corresponds to 100mg kg-' body weight.
The control group received intravenous saline on day 19.
After and during drug administration the animals were kept
in subdued light, with preservation of night/day rhythm.
and cooling to room temperature to destroy the activity of
uroporphyrinogen decarboxylase and to prevent further
metabolism of uroporphyrinogen.
Results are expressed per g of tissue and per mg of tissue
protein, measured by the method of Lowry et al. (1951). The
presentation per mg of tissue protein is generally used to
correct for the differences in tissue water content between
tissue samples.
Statistics
The values are expressed as mean ± standard error of the
mean (s.e.m.). Comparisons were made using the Mann-
Whitney U-test for day of recurrence, the Fisher exact pro-
bability test for lymph node metastasis and lung metastases,
and ANOVA for porphyrin concentrations. Differences were
considered significant when P-values were <0.05.
Results
Light delivery
Immediately after tumour resection on day 21 post inocula-
tion, in all groups the tumour bed was illuminated with a
'black-body' light source, emitting 320-450 nm (peak at
380 nm) with a power of 0.1 W cm-2. The lamp was kept at
a distance of 10 mm from the tissue surface for 10 min,
delivering a total energy of 60 J cm-2. Surrounding skin was
covered with black gauze to avoid normal tissue-damage and
the wound bed was irrigated during exposure to protect the
tissue from dehydration. The black-body light source was
chosen, as it is cheap, readily available and has proved to be
effective in destroying erythroleukaemic cells photosensitised
by incubation with ALA in vitro (Malik and Lugaci, 1987).
Score ofrecurrence, lymph node and lung metastasis
After treatment, the operation site was palpated daily to
identify tumour recurrence. Recurrence was considered when
regrowth to 10 mm in diameter had occurred. The day of
recurrence was then scored and the animal sacrificed. At
autopsy, lymph nodes (axillar, inguinal and para-aortal) were
examined bilaterally and the lungs were exposed to determine
metastases. When lymph nodes and lungs were macro-
scopically involved, they were scored positive. At day 28 post
treatment, the animals without signs of recurrence were also
killed and autopsied. A post-operative period of 28 days was
chosen, as in previous experiments all animals died within 20
days from disseminated disease.
Tissue porphyrin,ferrochelatase and PBGD measurements
On the day of primary tumour resection, in five animals
samples were taken from the periphery of the tumour with-
out central necrosis and from normal mammary tissue on the
contralateral site. The porphyrin analysis was carried out
according to Bayley and Needham (1986) with modifications
as described previously (Van Hillegersberg et al., 1992). The
tumour or mammary tissue was suspended in saline (1:10,
w/v) and homogenised in a tissue grinder. Each specimen was
analysed separately by reversed-phase high-performance
liquid chromatography (HPLC) and porphyrin fluorescence
detection with excitation and emission wavelengths of 405
and 625 nm respectively.
Ferrochelatase was measured by a modification of the
method of Li et al. (1987), using zinc and protoporphyrin as
substrates. Individual samples were homogenised in water
(1:10, w/w) and treated as described previously (Van
Hillegersberg et al., 1992). Zinc protoporphyrin was detected
using HPLC with fluorimetric detection (excitation 415 nm,
emission 580 nm). For comparison, the ferrochelatase was
also measured in rat fibrosarcoma BN175, inoculated sub-
cutaneously in four animals.
PBGD was measured as described previously (Wilson et
al., 1986), following an initial incubation at 55°C for 60 min
Of the 60 animals entering the study, three had to be killed
early because of extensive tumour growth. In one animal the
tumour did not take, and three animals had performed
autotomy at the operation site. In the remaining animals no
signs of discomfort or skin lesions could be observed. The
PDT did not cause any visible tissue changes to the exposed
abdominal wall tissue. Overall, 15 animals in the Photofrin
group, 19 in the ALA group and 19 in the control group
could be evaluated.
The mean ± s.e.m. tumour diameter at the day of treat-
ment was 25.9± 2.0, 25.9+ 1.5 and 27.4± 1.0mm in the
Photofrin, ALA and control group respectively. These
differences were not statistically significant.
Tumour-free interval
Figure 1 shows the tumour-free interval after surgical
excision and intraoperative PDT for the various groups. A
significant longer tumour-free interval was found after sur-
gical excision combined with adjuvant PDT vs surgery alone
(P<0.01). Median values were 25 days for Photofrin, 18
days for ALA and 14 days for controls. The difference
between photosensitisation with Photofrin or ALA was not
statistically significant. However, in the group treated with
Photofrin, 6 out of 15 (40%) animals were still without
recurrence 28 days post treatment, whereas this ratio was
only 3/19 (16%) after photosensitisation with ALA and 0/19
(0%) in controls.
Lymph node and lung metastasis
Table I shows the scores on tumour spread to lymph nodes
and lungs. When metastases had occurred, they were always
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Figure 1 Tumour-free interval after local resection followed by
adjunctive PDT with either Photofrin (5 mg kg- i.v., 48 h before
PDT), ALA (2mg ml- in drinking water for 9 days) or saline
i.v. (controls).
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inn. -Ilocated ipsilaterally in the axillary lymph nodes. Occasionally
positive para-aortal nodes were found (two in the ALA
group and four in controls). The involvement oflymph nodes
was significantly related to the type of adjuvant intra-
operative PDT applied (P<0.05). Remarkably, none of the
animals treated with Photofrin had positive lymph nodes,
even though a substantial part of the animals in this group
lived longer than the animals in the other two groups. After
ALA, around 30% of the animals had positive lymph nodes,
compared with 60% in the control group.
Differences in metastases to the lungs were statistically
non-significant, although a similar trend as with the lymph
nodes was found: Photofrin, 53%; ALA, 63%; controls,
74%.
Tissueporphyrin concentration,ferrochelatase and PBGD
activity
Figure 2 shows the total porphyrin accumulation in tumour
and normal breast tissue. In the control group, no significant
difference was found between the porphyrin concentration in
tumour (0.315 ± 0.05 nmol g-' tissue) and normal tissue
(0.233 ± 0.02 nmol g-' tissue). However, after photosensitisa-
tion with either Photofrin or ALA, porphyrins had
accumulated in both tissues, with higher values in tumour
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Figure 2 Total ± s.e.m. porphyrin concentration in tumour
( L ) and normal mammary tissue ( 3 ) after photosensitisa-
tion with either Photofrin (single 5 mg kg-' i.v. dose, 48 h
before), ALA (2 mgml1' in drinking water for 9 days) or saline
i.v. (controls).
TableI Numberofanimalswithmetastases inlymph nodes and lungs
after adjunctive PDT following tumour resectiona
No. of Lymph nodes + Lungs +
animals No. % No. %
Photofrinb 15 0 0 8 53
ALAC 19 6 32 12 63
Controlsd 19 12 63 14 74
aIllumination with 320-450 nm light of0.1 W cm-2 and 60 Jcm-2;
28 days' follow-up. b5 mg kg-' i.v. 48 h beforeillumination. C2 mgml-'
in drinking water for 9 days. dSaline i.v. Statistics - lymph nodes:
photofrin vs ALA, P<0.05; ALA vs controls, P<0.05; photofrin vs
controls P<0.01; lungs: non-significant.
Adjuvant PDTreducestumourrecurrence
R van Hillegersberg etal 4
735
(P<0.01). The chromatogram showed mainly protopor-
phyrin in the group treated with ALA, while in the other
group the typical peaks of the Photofrin components were
found as described previously (Van Hillegersberg et al.,
1992). After Photofrin, the mean ± s.e.m. porphyrin concent-
ration was 0.974 ± 0.12 nmol g-' in tumour and 0.444 ± 0.09
nmol g' in normal tissue, leading to a ratio of 2:1. After
ALA, these values were 1.969 ± 0.24 nmolg-I in tumour
compared with 0.549 ± 0.08 nmol g' in normal tissue,
leading to a porphyrin concentration ratio of 4:1.
The ferrochelatase activity was 0.62 ± 0.04 nmol h-' of
zinc-PROTO per mg of protein in mammary tumour and
0.22 ± 0.01 nmol h-' mg-' protein in normal breast tissue
(Table II). The tumour value is in the same range as that
measured for rat fibrosarcoma (0.49 ± 0.02 nmolh'-I mg'I
protein) and rat colon carcinoma CC531 (0.84 ± 0.10 nmol
h' mg-' protein) which showed a 3-fold lower activity than
normal liver (2.47 ± 0.26 nmol h-1mg'I protein) (Van
Hillegersberg et al., 1992). PBGD showed an activity in
tumour (34 ± 2 x 10-3 nmolh-I of URO per mg of protein)
similar to that in normal breast tissue (30 ± 2 x 10-3 nmol
h-' mg'1 protein).
Discussion
In this study adjuvant intraoperative PDT caused a substan-
tial prolonged recurrence-free interval in rats, following sur-
gical excision of the subcutaneously implanted mammary
tumour. The treatment did not cause complications or any
visible damage to the exposed normal tissue, suggesting that
intraoperative PDT can be applied safely. Remarkably,
although no effect on metastases to the lungs was found,
lymph node metastasis was significantly reduced in the
groups treated with PDT. In the Photofrin group none of the
animals had positive nodes, compared with 6/19 rats in the
ALA group and 12/19 controls. The mechanism of this addi-
tional PDT effect is not clear, but it might be caused by a
direct effect on the lymphatic vessels in the illuminated area.
There was no statistically significant relation between the
method of photosensitisation and the rate of tumour recur-
rence, although 28 days post treatment 40% of the animals
were still without recurrence after Photofrin, compared with
only 16% after ALA. This may suggest that Photofrin is a
better photosensitiser than protoporphyrin IX induced by
administration of ALA. However, the results may not be
completely comparable, as the optimal light delivery regimen
could be different for photosensitisation with endogenously
produced porphyrins. The protoporphyrin molecule may be
more susceptible to reaction with singlet oxygen or tissue
components during illumination (photobleaching) (Kennedy
and Pottier, 1992). Photobleaching competes with the
photodynamic reaction and the porphyrin products do not
contribute to further photodynamic activity (Mang et al.,
1987). Therefore, periodic illumination or prolonged
exposure with lower output power may improve efficacy by
allowing regeneration of sufficient levels of unbleached pro-
toporphyrin (Joseph et al., 1993). Furthermore, a different
intracellular localisation of the endogenous porphyrin may
have its consequences for the PDT effect.
After ALA, a higher and more favourable tumour to
normal tissue porphyrin concentration was found (4:1), com-
Table II Ferrochelatase and porphobilinogen deaminase activity in rat tumours, normal liver and breast
Ferrochelatase Porphobilinogen deaminase
nmolh-' ofzinc-PROTO nmolh-' of URO
Tissue type per g tissue per mgprotein per g tissue per mgprotein ( x 10-3)
Mammary carcinoma BN472a 66 5 0.62 ± 0.04 3.68 ± 0.18 34 ±2
Fibrosarcoma BN175b 52 4 0.49 ± 0.02 3.50 ± 0.14 34 ± 2
Colon carcinoma CC531C 100 ± 12 0.84 ± 0.10 5.93 ± 0.60 49± 5
Liver' 541 + 58 2.47 + 0.26 17.0 + 0.5 79 ± 2
Breasta 6.2 0.6 0.22 0.01 0.87 0.14 30 2
Data represent the mean ± s.e.m. ofa5, b4 and c II samples; cfrom Van Hillegersberg et al. (1992).
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pared with Photofrin (2:1). In a previous study in intra-
hepatic rat colon carcinoma, we found a similar ratio of
tumour to normal liver after ALA, whereas for Photofrin the
ratio was almost reversed (1:3) (Van Hillegersberg et al.,
1992). Remarkably, in that study higher tissue porphyrin
concentrations (up to a factor of 20) were found. As the
activity of ferrochelatase is in the same range for both
tumours (Table II), this might be caused by a higher uptake
of ALA in liver as a result of (1) a better vascular supply of
hepatic tissue or (2) preferential targeting to the liver, which
is one of the main sites of haem biosynthesis in humans
(Bottomley and Muller-Ebenhard, 1988). The low activity of
ferrochelatase found in normal breast tissue can be explained
by the high fat content with little porphyrin metabolism.
Therefore, the values given in Table II are probably not
representative for the real enzyme activity in mammary gland
tissue. As fat cells contain proteins as well, the representation
per mg of protein leads to an additional unclear transforma-
tion of these values. Actually, as both PBGD and ferro-
chelatase are located in mitochondria, a representation per
number of tissue mitochondria would have been a better
option. However, other mitochondrial enzymes that could be
used as a marker for the number of mitochondria may have
altered activities in tumour as well. The reason for low
ferrochelatase activity in tumours may be the use of
glycolysis rather than oxidative phosphorylation for their
metabolism. In particular, rapdily growing tumours contain
lower activities of mitochondrial cytochrome oxidase (Smith,
1987). Mitochondrial ferrfchelatase would therefore be
deficient secondary to deficiencies in mitochondrial cytoch-
rome oxidase (Rimington and Riley, 1993). A promising
option to increase endogenous porphyrin accumulation is the
modification of the enzymes responsible for porphyrin
biosynthesis. Substances such as griseofulvin and hexach-
lorobenzene have already been used to induce porphyrin
accumulation in hepatic cells in vitro (Visser et al., 1991).
More recently, 1,10-phenanthroline has been shown to dou-
ble the amount of ALA-induced protoporphyrin accumula-
tion in rapidly proliferating cells (Rebeiz et al., 1992).
In this study, we used a light source emitting 320-450 nm
(peak at 380 nm) to activate the accumulated porphyrins at
their highest absorption peak at 400 nm. Mostly the weaker
peak at 625 nm is used, as light of this wavelength penetrates
deeper into the tissue (Star et al., 1990). However, in the
intraoperative adjuvant application of PDT, tissue penetra-
tion may not be crucial since the tumour bulk has been
removed surgically and only residual tissue of not more than
millimetres in thickness has to be eliminated. To determine
the influence ofwavelength, Lantz et al. (1992) compared the
effect of the copper metal vapour laser (mainly 510.5 nm)
and the rhodamine argon-pumped dye laser (630 nm) at 150 J
cm-' in a mouse colon carcinoma photosensitised with
Photofrin. They found a similar depth of necrosis (4-5 mm)
with both lasers. However, it has to be noted that the copper
vapour laser also induced hyperthermia of >40°C, which has
been shown to potentiate PDT (Waldow et al., 1987). In
another study by Davis et al. (1990), surgical resection and
intraoperative PDT at 630 nm resulted in 60% tumour recur-
rence ofa mouse neuroblastoma, whereas the same treatment
at 488-514 un (argon laser) resulted in only 20% recurrence.
In that study, the additional effect of hyperthermia was
clearly demonstrated, as laser illumination alone substantially
reduced the recurrence rate. The advantage of the copper
metal vapour laser would be the much higher power output
(25 W), producing a 30-60cm2 beam of 0.5-1 W cm-2. The
dye lasers currently available deliver only 2-4W at 625 nm,
requiring exposure times of several hours to treat clinically
relevant tissue areas.
There are only few other studies on the use of PDT as an
adjunct to curative surgery. Herrera-Ornelas et al. (1986) and
Nambisan et al. (1988) demonstrated the feasibility of this
approach in patients undergoing resection of recurrent col-
orectal carcinoma and retroperitoneal sarcoma. Delaney et al.
(1993) completed a phase I feasibility study ofPDT following
debulking surgery for disseminated intraperitoneal tumours.
In an attempt to illuminate the tissue surfaces equally, special
light delivery devices were constructed consisting of a single
fibre embedded in a balloon filled with diffusing Intralipid.
To apply sufficient light energy to the large surface ares, two
argon dye laser systems were used simultaneously at 514 nm.
Light of 630 nm, which could only be delivered at a lower
power output, was used when deeper tissue penetration was
required. The intra-abdominal organs were found to be
rather sensitive, and maximal tolerable light doses were set at
3.75 J cm-2 of 514 nm (48-72 h post 2.5 mgkg-' Photofrin
injection). Abulafi et al. (1992, 1993) have initiated a phase
III clinical trial of adjuvant intraoperative PDT for resection
of colorectal carcinoma vs surgery alone. A simhilar light
delivery system was used at 510 nm, 35-70 J cm 2, delivered
48 h after 2 mgkg-' Photofrin intravenously. An interim
analysis of43 patients (median follow-up 12 months) did not
show a significant difference in survival rate. However, in a
subgroup with proved positive resection margins only 1/8
developed local recurrence after adjuvant PDT vs 12/14 after
surgery alone. These preliminary results may indicate that a
more aggressive approach with light of 630 nm is needed to
completely eradicate residual tumour.
In conclusion, adjuvant intraoperative PDT seems to be a
promising approach to sterilise the tumour bed after tumour
debulking surgery. Clinical applications have mainly focused
on the intra-abdominal use, in which sufficient light delivery
and dosimetry have been a major drawback (Evrard et al.,
1993). However, the method is potentially applicable to
various other locations, including breast cancers requiring a
mastectomy.
Acknowledgements
The authors thank Mr P Moonen (Quadra Logic Technologies, The
Netherlands) for generously supplying the Photofrin.
References
ABULAFI AM, ALARDICE JT AND WILLIAMS NS. (1992). Adjunctive
intraoperative photodynamic therapy for colorectal cancer.
Lasers Surg. Med., Suppl. 4, 49.
ABULAFI AM, ALARDICE JT AND WILLIAMS NS. (1993). A phase
III study on the effect of adjunctive intraoperative photodynamic
therapy in colorectal cancer: an interim report. Lasers Surg.
Med., Suppl. 5, 45.
AMES FC AND BALCH CM. (1990). Management of local and
regional recurrence after mastectomy and breast-conserving treat-
ment. Surg. Clin. N. Am., 70, 1115-1124.
BAYLEY GG AND NEEDHAM LL. (1986). Simultaneous quan-
tification of erythrocyte zinc protoporphyrin and protoporphyrin
IX by liquid chromatography. Clin. Chem., 32, 2137-2142.
BELLNIER DA, HO YK, PANDEY RK, MISSERT JR AND DOUGH-
ERTY TJ. (1989). Distribution and elimination of Photofrin II in
mice. Photochem. Photobiol., 50, 221-228.
BOTTOMLEY SS AND MULLER-EBENHARD U. (1988). Pathophysio-
logy of haem synthesis. Semin. Hematol., 25, 282-302.
BUYSE M, ZELENIUCH-JACQUOTTE A AND CHALMERS TC. (1988).
Adjuvant therapy of colorectal cancer: why we still don't know.
JAMA, 259, 3571-3611.
DAVIS RK, SMITH LF, THURGOOD RF, KERESZTI A AND
STRAIGHT RC. (1990). Intraoperative phototherapy (PDT) and
surgical resection in a mouse neuroblastoma model. Laser Surg.
Med., 10, 275-279.
DELANEY TF, SINDELAR WF, TOCHNER Z, SMITH PD, FRIAUF WS,
THOMAS G, DACHOWSKI L, COLE JW, STEINBERG SM AND
GLATSTEIN E. (1993). Phase I study of debulking surgery and
photodynamic therapy for disseminated intraperitoneal tumours.
Int. J. Radiat. Oncol. Biol. Phys., 25, 445-457.
DOUGHERTY TJ. (1993). Photodynamic therapy. Photochem. Photo-
biol., 58, 895-900.
EVRARD S, APRAHAMIAN M AND MARESCAUX J. (1993). Intra-
operative photodynamic therapy: from theory to feasibility. Br. J.
Surg., 80, 298-303.Adjuvant PDTreducestumour recurrence
R van Hillegersberg etal S
737
FRAZIER TG, WONG RWY AND ROSE D. (1989). Implications of
accurate pathological margins in the treatment of primary breast
cancer. Arch. Surg., 124, 37-38.
FISHER B, REDMOND C, POISSON R, MARGOLESE R, WOLMARK
N, WICKERHAM L, FISHER E, DEUTSCH M, CAPLAN R, PILCH
Y, GLASS A, SHIBATAT H, LERNER H, TERZ J AND SIDORO-
VICH L. (1989). Eight years results of randomized clinical trial
comparing total mastectomy and lumpectomy with or without
irradiation in the treatment of breast cancer. N. Engl. J. Med.,
320, 822-828.
GALANDIUK S, WIEAND HS, MOERTEL CG, CHA SS, FITZGIBBONS
RJ, PEMBERTON JH AND WOLFF BG. (1992). Patterns of recurr-
rence after curative resection of carcinoma of colon and rectum.
Surg. Gynecol Obstet., 174, 27-32.
GOMER CJ. (1989). Photodynamic therapy in the treatment of malig-
nancies. Semin. Hematol., 26, 27-34.
HERRERA-ORNELAS L, PETRILLI NJ, MITTELMAN A AND DOUGH-
ERTY TJ. (1986). Photodynamic therapy in patients with colorec-
tal cancer. Cancer, 57, 677-684.
HOLLAND R, VELING SHJ, MRAVUNAC M AND HENDRIKS JHCL.
(1985). Histologic multifocality of Ti, T1.2 breast carcinomas.
Cancer, 56, 979-990.
JOSEPH R, GOFSTEIN G AND JACQUES S. (1993). Photobleaching of
5-aminolevulinic acid induced protoporphyrin IX. Lasers Surg.
Med., ?, Suppl. 5, 46.
KAYAHARA M, NAGAKAWA T, UENO K, OHTA T, TAKEDA T AND
MIYAZAKI I. (1993). An evaluation of radical resection for pan-
creatic cancer based on the mode of recurrence as determined by
autopsy and diagnostic imaging. Cancer, 72, 2118-2123.
KENEDY JC AND POTTIER RH. (1992). Endogenous protoporphyrin
IX, a clinically useful photosensitizer for photodynamic therapy.
J. Photochem. Photobiol., 14, 275-292.
KORT WJ, HULSMAN LOM, WEIJMA IM, ZONDERVAN PE AND
WESTBROEK DL. (1986a). Influence ofthe linoleic acid content of
the diet on tumour growth in transplantable rat tumour models.
Ann. Nutr. Metab., 30, 120-128.
KORT WJ, ZONDERVAN PE, HULSMAN LO, WEIJMA IM AND
WESTBROEK DL. (1986b). Light-dark-shift stress, with special
reference to spontaneous tumour incidence in female BN rats. J.
Nati Cancer Int., 76, 439-446.
LANTZ JM, MEYER C, SAUSSINE C, LEBERQUIER C, HEYSEL F,
MIEHE J, MARESCAUX J, SULTAN R AND KEDINGER M. (1992).
Experimental photodynamic therapy with a copper metal vapor
laser in colorectal cancer. Int. J. Cancer, 52, 491-498.
LI F, LIM CK AND PETERS TJ. (1987). An HPLC for rat liver
ferrochelatase activity. Biomed. Chromatogr., 2, 164-168.
LOH CS, MACROBERT AJ, BEDWELL J, REGULA J, KRASNER N
AND BOWN SG. (1993). Oral versus intravenous administration of
5-aminolaevulinic acid for photodynamic therapy. Br. J. Cancer,
68, 41-51.
LOWRY H, ROSEBOURGH NJ, FARR AL AND RANDALL RJ. (1951).
Protein measurement with the folin-phenol reagent. J. Biol.
Chem., 193, 265-275.
MACMILLAN RD, PURUSHOTHAM AD, MALLON E, RAMSAY G
AND GEORGE WF. (1994). Breast-conserving surgery and tumour
bed positivity in patients with breast cancer. Br. J. Surg., 81,
56-58.
MALIK Z AND LUGACI H. (1987). Destruction of erythroleukaemic
cells by photoactivation ofendogenous porphyrins. Br. J. Cancer,
56, 589-595.
MANG TS, DOUGHERTY TJ, POTTER WR, BOYLE DG, SOMER S
AND MOAN J. (1987). Photobleaching of porphyrins used in
photodynamic therapy and implications for therapy. Photochem.
Photobiol., 45, 501-506.
MOERTEL CG, FLEMING TR, MACDONALD JS, HALLER DG,
LAURIE JA, GOOMAN PJ, UNGERLEIDER JS, EMERSON WA,
TORMEY DC, GLICK JH, VEEDER MH AND MAILLAIRD JA.
(1990). Levamisol and 5FU for adjuvant therapy of resected
colon carcinoma. N. Engl. J. Med., 322, 352-358.
NAMBISAN RN, KARARKOUSIS CP, HOLYOKE ED AND DOUGH-
ERTY TJ. (1988). Intraoperative photodynamic therapy for retro-
peritoneal sarcomas. Cancer, 61, 1248-1252.
POTTIER R, CHOW YFA, LAPLATE JP, TRUSCOTT TG, KENNEDY JC
AND BEINER LA. (1986). Non-invasive technique for obtaining
fluorescence excitation and emission spectra in vivo. Photochem.
Photobiol., 44, 679-687.
RAZUM N, BALCHUM OJ, PROFIO AE AND CARSTENS F. (1987).
Skin photosensitivity: duration and intensity following intra-
venous hematoporphyrin derivatives HpD and DHE. Photochem.
Photobiol., 46, 925-928.
REBEIZ N, REBEIZ CC, ARKINS S, KELLEY KW AND REBEIZ CA.
(1992). Photodestruction in tumour cells by induction of
endogenous accumulation ofprotoporphyrin IX: enhancement by
1,10-phenanthroline. Photochem. Photobiol., 55, 431-435.
RIMINGTON C AND RILEY PA. (1993). The biochemical approach to
cancer therapy: a short assay. Int. J. Biochem., 25, 1385-1393.
SCHOENFELD N, EPSTEIN 0, LAHAV M, MAMET R, SHAKLAI M
AND ATSMON M. (1988). The haem biosynthetic pathway in
lymphocytes of patients with malignant lymphoproliferative
disorders. Cancer Lett., 43, 43-48.
SMITH A. (1987). Mechanisms of toxicity of photoactivated artificial
porphyrins: role of porphyrin-protein interactions. Ann. NY
Acad. Sci., 514, 309-322.
STAR W, VERSTEEG JC, VAN PUTrEN W AND MARIJNISSEN HA.
(1990). Wavelength dependence of hematoporphyrin derivative
photodynamic treatment effects on rat ears. Photochem. Photo-
biol., 52, 547-554.
VAN HILLEGERSBERG R, VAN DEN BERG JWO, KORT WJ, TERPSTRA
OT AND WILSON JHP. (1992). Selective accumulation of
endogenously produced porphyrins in a liver metastasis model in
rats. Gastroenterology, 103, 647-651.
VISSER 0, VAN DEN BERG JWO, KOOLE-LESUIS R, VORTMAN G
AND WILSON JHP. (1991). Porphyrin synthesis by human
hepatocytes and HepG2 cells: effects of enzyme inducers and
delta-aminolevulinic acid. Toxicology, 67, 75-83.
WALDOW SM, HENDERSON BW AND DOUGHERTY TJ. (1987).
Hyperthermic potentiation of photodynamic therapy employing
Photofrin I and II: comparison of results using three animal
tumour models. Lasers Surg. Med., 7, 12-22.
WESTERDAHL J, ANDREN-SANDBERGEN A AND IHSE I. (1993).
Recurrence of exocrine pancreatic cancer - local or hepatic?
Hepatogastroenterology, 40, 384-387.
WILSON JHP, DE ROOY FWM AND TE VELDE K. (1986). Acute
intermittent porphyria in the Netherlands: heterogeneity of the
enzyme porphobilinogen deaminase. Neth. J. Med., 29, 393-399.